|
|
|
| Surveillance of hepatitis C among five high-risk populations in Inner Mongolia Autonomous Region from 2013 to 2021 |
| LIU Yingnan1,2, YANG Jingyuan2, LI Hui2, YANG Hong2, GAO Baicheng2, GAO Ya2, LI Xiangchun2, CAO Meng2
|
1. School of Public Health,Inner Mongolia Medical University, Hohhot, Inner Mongolia 010110, China;
2. Inner Mongolia Autonomous Region Comprehensive Center for Disease Control and Prevention, Hohhot, Inner Mongolia 010080, China |
|
|
|
|
Abstract Objective To investigate the prevalence of hepatitis C virus (HCV) infections among five high-risk populations in Inner Mongolia Autonomous Region, so as to provide insights into improvements in the control strategy for hepatitis C. Methods The detection of anti-HCV antibody was collected from patients receiving renal dialysis, patients receiving invasive diagnosis and treatment in hospitals, physical examination populations, unpaid blood donors and subjects admitted to family planning clinics in national hepatitis C surveillance sentinels in Inner Mongolia Autonomous Region from 2013 to 2021, and the year-, gender- and age-specific prevalence of anti-HCV antibody was analyzed. Results The mean prevalence of anti-HCV antibody was 2.19%, 1.81%, 0.05%, 0.10% and 0.03% among 3 600 patients receiving renal dialysis, 3 600 patients receiving invasive diagnosis and treatment in hospitals, 18 000 physical examination populations, 18 000 volunteer blood donors and 3 600 subjects admitted to family planning clinics, respectively. The prevalence of anti-HCV antibody appeared a tendency towards a decline among patients receiving renal dialysis (χ2trend=49.065, P<0.001) and volunteer blood donors (χ2trend=11.419, P=0.001). The prevalence of anti-HCV antibody was higher among male patients receiving invasive diagnosis and treatment in hospitals than among females (2.34% vs. 1.36%; χ2=4.826, P=0.028), and no gender-specific prevalence of anti-HCV antibody was seen among other four high-risk populations (all P>0.05). The highest prevalence of anti-HCV antibody was detected among patients receiving renal dialysis (3.30%) and patients receiving invasive diagnosis and treatment in hospitals at ages of 50 to 59 years (3.35%), while the highest prevalence was found among physical examination populations at ages of 60 years and greater (0.18%). Conclusion The prevalence of anti-HCV antibody was high among patients receiving renal dialysis and patients receiving invasive diagnosis and treatment in hospitals and low among physical examination populations, volunteer blood donors and subjects admitted to family planning clinics in Inner Mongolia Autonomous Region from 2013 to 2021. Periodical monitoring of anti-HCV antibody is recommended among the elderly.
|
|
Received: 21 April 2022
Revised: 17 June 2022
Published: 08 September 2022
|
|
|
|
|
|
[1] MELKU M,AMBACHEW S,ENAWGAW B,et al.Sero-epidemiology and associated factors of HIV,HBV,HCV and syphilis among blood donors in Ethiopia:a systematic review and meta-analysis[J/OL].BMC Infect Dis,2021,21(1)[2022-06-17].https://doi.org/10.1186/s12879-021-06505-w.
[2] NGUYEN D B,BIXLER D,PATEL P R.Transmission of hepatitis C virus in the dialysis setting and strategies for its prevention[J].Semin Dial,2019,32(2):127-134.
[3] PONNUVEL S,FLETCHER GJ,ANANTHARAM R,et al.Clinical utility of hepatitis C virus core antigen(HCVcAg)assay to identify active HCV infection in hemodialysis and renal transplant patients[J/OL].PLoS One,2021,16(4)[2022-06-17].https://doi.org/10.1371/journal.pone.0250263.
[4] 丁国伟,叶少东,黑发欣,等.2016—2017年中国丙型肝炎哨点监测分析[J].中华流行病学杂志,2019,40(1):41-45.
DING G W,YE S D,HEI F X,et al.Sentinel surveillance for viral hepatitis C in China,2016-2017[J].Chin J Epidemiol,2019,40(1):41-45.
[5] 葛琳,王岚,丁正伟,等.中国2010—2012年丙型肝炎哨点5类监测人群HCV感染状况分析[J].中国艾滋病性病,2013,19(11):812-815.
GE L,WANG L,DING Z W,et al.Analysis on HCV prevalence among 5 kinds of populations in HCV sentinel surveillance during 2010-2012 in China[J].Chin J AIDS STD,2013,19(11):812-815.
[6] 庄辉. 丙型肝炎病毒实验室检测技术规范[S].北京:中国疾病预防控制中心,2011.
ZHUANG H.Technical specifications for laboratory testing of hepatitis C virus[S].Beijing:Chinese Center for Disease Control and Prevention,2011.
[7] 缪兴全,王超然,曾翠,等.血液透析室丙型肝炎病毒暴发事件的分析与防控[J].中国感染控制杂志,2020,19(12):1140-1144.
MIAO X Q,WANG C R,ZENG C,et al.Prevention and control of hepatitis C virus outbreak event in hemodialysis room[J].Chin J Infect Control,2020,19(12):1140-1144.
[8] WU P Y,HUNG M N,HUANG W L,et al.Hepatitis C outbreak in a respiratory care ward associated with frequent injections:Taiwan,2017[J].J Microbiol Immunol Infect,2021,54(5):893-900.
[9] RAHAT M A,ISRAR M,HASSAN I,et al.Episode of hepatitis C viral infection in the people of Swat,Pakistan[J].Braz J Biol,2021,82[2022-06-17].https://doi.org/10.1590/1519-6984.243283.
[10] 吴传芳,谢和宾,姚小红,等.维持性血液透析患者丙型肝炎病毒感染的危险因素与控制进展[J].中国血液净化,2015,14(4):234-236.
WU C F,XIE H B,YAO X H,et al.Risk factors and control progress of hepatitis C virus infection in maintenance hemodialysis patients[J].Chin J Blood Purif,2015,14(4):234-236.
[11] 陈园生,李黎,崔富强,等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志,2011,32(9):888-891.
CHEN Y S,LI L,CUI F Q,et al.A sero-epidemiological study on hepatitis C in China[J].Chin J Epidemiol,2011,32(9):888-891.
[12] 刘锋,方奎明,黄志翔,等.岳阳地区献血人群丙型肝炎病毒感染情况调查[J].现代医药卫生,2021,37(22):3816-3818.
LIU F,FANG K M,HUANG Z X,et al.Investigation of hepatitis C virus infection among blood donors in Yueyang[J].J Mod Med Health,2021,37(22):3816-3818.
[13] 王桂玲,赵有莲,王治海.青海地区无偿献血人群HBV、HCV、HIV感染检测分析[J].华南预防医学,2021,47(11):1420-1423.
WANG G L,ZHAO Y L,WANG Z H.Prevalence of HBV,HCV and HIV infection among unpaid blood donors in Qingha[J].South Chin J Prev Med,2021,47(11):1420-1423.
[14] 周丹,刘晓楠,孙笠翔,等.2015—2019年辽宁省五类人群丙肝监测结果分析[J].预防医学,2021,33(4):354-357.
ZHOU D,LIU X N,SUN L X,et al.Hepatitis C prevalence among five kinds of populations monitored in Liaoning Province from 2015 to 2019[J].Prev Med,2021,33(4):354-357.
[15] 马晶,王梅,谯小伟,等.兰州市2010—2019年丙型肝炎流行特征[J].中华疾病控制杂志,2020,24(9):1087-1091.
MA J,WANG M,QIAO X W,et al.Epidemic characteristics of hepatitis C in Lanzhou City from 2010 to 2019[J].Chin J Dis Control Prev,2020,24(9):1087-1091. |
|
|
|
